Biotech startup Zumutor Biologics has raised USD 4 million in the latest funding from the Bharat Innovation Fund and Accel Partners taking its total tally to USD 20 million.
The Bangalore-based company focuses on novel monoclonal antibody therapeutics against innate immunity targets.
The fresh capital will be used for the process of new drug filing of its lead molecule(ZM 008) in India, and to go through the first phase of clinical trials by the end of 2020.
“Our first-in-class lead molecule, ZM 008 has made industry validated progress and is poised for IND filing with Phase 1a/1b clinical trials likely to commence end of 2020,” Kavita Iyer Rodrigues, founder and CEO of Zumutor Biologics, told Economic Times.
Zumutor’s high diversity human antibody libraries serve as powerhouse for developing novel monoclonal antibody therapeutics targeting various immuno oncology pathways. Their product pipeline constitutes unique immuno-oncotherapeutics that target innate immunity and regulate tumor micro environment
“The strong pipeline that Zumutor has developed combined with a relatively differentiated NK cell approach could lead to breakthrough treatments for multiple cancers,” Ashwin Raguraman, Founding Partner, Bharat Innovation Fund told Economic Times.
In India, Zumutor Biologics competes with tech startups such as NIRAMAI, Mitra Biotech, OncoStem Diagnostics, Sascan, Exocan, and Onward Health.